sapien biobank isber 08 may 2015_jain
TRANSCRIPT
Bio-banking & Clinical Diagnostics
Translational Science, Personalized Medicine
SAARUM SCIENCES
Phenotypic Drug Discovery
Vision and Mission of Biobank
12 May 2015 2
Vision:
To be a premier global biotech that employs human translational platforms for the discovery & development of novel diagnostics, biomarkers & drugs with better clinical outcomes
Mission:
• Build a systematic Biobank of ethically consented, high quality, geographically diverse human samples and associated medical data,
• Utilize these curated samples for developing novel biomarkers & diagnostics, modeling human disease, discovering drug targets & drugs with higher rates of clinical success
• Use tissues for R&D, NOT for regenerative medicine or transplantation
Sapien Biosciences
Bio-Bank
Exclusive*, network-wide access to tissues
Cash Funding
Alliance with Apollo Hospitals
12 May 2015 3
Incubation space & equipment
Serie
s B In
vesto
rs
• Bio-Banking• Personalized Med•Diagnostics R&D
• Phenotypic Screening•Disease Modeling• Target Disc & Validation
Ap
ollo
Ho
spit
als
Sapien and Saarum are sister companies; Saarum has access to Sapien’s samples for its R&D* Sapien is not exclusive to Apollo, it gets samples from other hospitals also
Sapien Biosciences
12-May-15 4
FY14 at Apollo hospitals
A typical weekday in the world of Apollo
The Apollo set-up – Asia’s largest hospital networkThe Apollo advantage
An abundant resource of diseased tissue samples and an honest will to use them for betterment of mankind- contributing to diagnostics and drug development - offering these new drugs / diagnostics for their patients
Footfalls Admissions Surgeries CT Scans MRIs300MRIs
600CT-Scans
20,000Footfall
1,500Admissions
800Major
Surgeries
1000Health checks
3-4 Organ
Transplants
350Dialysis
40Cardiac
surgeries
100,000+Pharmacy walk ins
• Cumulative experience of over 800 trials with 70% of these for FDA or EU registration
• Potential to undertake more than 200 trials at any given time
12-May-15 5
Access to clinical network: Apollo Research and Innovation
Standardized SOPs
Clinical Trials Management System(CTMS)
17 networked sites
Resources
Highly Vigilant Ethics Committees
60 GCP trained CR Coordinators
200 GCP trained PIs
Reach
54 Apollo Hospitals
72 Apollo Clinics
Processes
Over 100 clinicians willing to participate
Current trials across therapeutic areas
Ethical Framework for Biobanking @ Sapien
• Sapien works within ICMR (Indian) and international guidelines
• Requirement for informed consent is waived for retrospective samples. These can be anonymized and banked with Ethics Committee approval (ICMR Guidelines, 2006)
• Sapien banks retrospective samples ‘left-over’ from procedures, with Hospital EC approval
• Approvals obtained from Apollo Ahmedabad, Bangalore, Chennai, Delhi, Kolkata and Hyderabad ECs to collect retrospective pathology blocks
• Sapien banks prospective samples where an additional sample is collected for a study with hospital EC approval and with Informed Consent from patients
• Informed consent language follows ICMR guidelines
• Sapien’s or Saarum’s IRB reviews use of such samples for specific projects
12 May 2015 6Sapien Biosciences
12-May-15 Sapien Biosciences 7
Type of Human Samples Banked at Sapien
• Retrospective, old left-over blocks dating back to ~15 yrs
• FFPE blocks – Tumors & adjacent non-tumor, other diseasesAlso non-diseased patient blocks
• Prospective samples - with informed consent
• Fresh tumor and adjacent non-tumor samples **• Hematol. tumors: Cell types (PBMCs, T/B cells, platelets etc.)• Blood, Plasma, Serum• Saliva, Urine, BAL, Pleural fluid, synovial fluid etc. • Non-diseased specimens
• Health Check-up left-over samples - with informed consent
• Serum / Blood / Urine - With rich associated data
~30,000 patients’ blocks & data currently at Sapien. Expect 500,000 samples in ~5 yrsfrom just the Apollo network
~ 700 patients’ fresh samples at Sapien. Can collect ~50,000 fresh samples in 5 years
** Matched blocks/fresh tissue/cells, plasma/DNA in many cases
Retrospective FFPE Block Retrieval
12 May 2015 8
Dec 2013 - Sample retrieval launched from Hyderabad site
~8000
October 2014
Chennai initiated
~15000
January 2015
Delhi initiated
~30000
May 2015
Kolkata initiated
December 2013
Hyderabad initiated
2200
Sapien Biosciences
Retrospective Formalin Fixed Blocks @ Sapien – Organ wise distribution
* Data from single location - Apollo Hyderabad for ~3 yrs. Sapien is systematically retrieving samples from across Apollo network over several years
Distribution of Diseases – Retrospective Formalin Fixed Blocks (For just 1 year at 1 site)
Cancers comprise approx. half of the retrospective formalin fixed blocks at Apollos- Cancer tissues span benign to metastatic
12 May 2015 10Sapien Biosciences
12-May-15 Sapien Biosciences 11
Prospective Samples @ Sapien
Accessibility across Apollos – Can source many sample types and diseases based on requirement
Specific protocol-based EC approvals obtained for projects
Fresh tissues @ Sapien - Currently banked / feasible to source Abdominal cavity Tonsil Parathyroid Malignant Lymph nodes Surgical resection of Adenoids
Bladder Glossectomy Parotid Laryngectomy Surgical resection of the spleen
Brain Thyroid Pancreas Uterus Surgical resection of Tonsils
Breast Testis Ovary Prostate Fibroids from uterus
Kidney Stomach Omentum Penis Spinal Tumors, CSF
Colon Spleen Oesophagus Normal Lymph nodes Liposuction
Buccal Mucosa Spinal Cord Lung Male normal breast reduction Vitreous gel from eye
Gluteal Region Rectum Liver Female normal Breast reduction Synovial fluid
Cervix Skin Non malignant hysterectomy sample Cord Blood
Sapien’s Database Captures Wealth of Information on Indian Diseases and Response to Treatment by Indian Patients
12-May-15 Sapien Biosciences 12
First implementation of NCI’s caTissue database in India (Krishagni partnership)
Any specific inclusion / exclusion criteria can be set as per need of project
Demographics
PathologyFamily History
Visits History
Recurrence follow ups
Treatment information
Diagnostic data
Disease severity /
status
Molecular classification
Recorded routinely with all samples
Obtained on a case-by-case basis for specific projects
12 May 2015 13
Example CVD-T2D-Obesity• Matched DNA, plasma, urine etc. left-over from Apollo health checks can be banked• Can be associated with the biochemical data from health check• Age-matched samples from diseased vs. non-diseased individuals can be compared• Longitudinal follow-up data can be collected• Can study outcomes along the lines of Framingham Risk Score
• The database can be mined in many ways: disease treatment outcomes, demographics, genetic correlation to response to drugs, identification of risk factors for diseases etc.• Contribute to Indian Registry?
• Approach can be extended to other disease-specific database of samples and EMRs• Oncology : Matched sets of fresh live & fresh frozen tissue, formalin fixed block, blood, BM, urine• Inflammation, Opthalmology, CNS• Maternal and Childhood diseases: CF, Autism, • Rare monogenic diseases - ORDI
Sapien Biosciences
Sapien’s EMR Database – Knowledge-base
BUILDING SUSTAINABILITY
Case Studies in Diagnostics and R&D Services
Sapien-Saarum
Services Provided by the Biobank Benefit Many Groups
12 May 2015 15
BIOBANK
Prognostics: Predicting Disease Occurrence Risk
Diagnostics:Precisely
diagnosing disease
Theranostics:Optimizing Drug
Treatment
Treatments: Pharma/Biotech:
Companion diagnostic
development Research Tools: Tissue Microarrays,
Indian Cell Line bank
Custom Biobanking:
Creating custom repository
Sapien- Saarum
Global Life Sciences Industry and Academia
Academiclabs andHospitals
Indian Patients
Using Sapien’s Depth in Breast Cancer to Validate Recurrence Markers
Breast cancer recurrence diagnostics can help
• in optimizing effective treatment and avoiding excessive chemo/ radio therapy associated with severe side effects (~50% ER/PR+ patients do not recur)
• prescribing new targeted drugs to make therapy more effective (~25% ER-/PR- cancers do recur)
• Sapien- Oncostem partnership for validation of IHC-based biomarker panel focused on aggressiveness of cancer to better predict the risk of recurrence in five years
• Collating samples from ~2000 retrospective patients diagnosed with Stage 1, 2 & 3A breast cancer along with
• Full associated pathology, medical treatment history, recurrence and 5 year outcomes data
Upon successful completion, Sapien realizes milestones and royalties, and commercializes the test across Apollo network and partner hospitals
12 May 2015 Sapien Biosciences 16
Growing Size and Depth of Sapien’s Breast Cancer Collection
Hyderabad, 164
Delhi, 364
Chennai, 330
CURRENT INVENTORY = 858+* 16
103
302
177
121
7448
17
Inventory based on cancer stage
0 1 2A 2B 3A 3B 3C 4
• Work in progress for ~400 more cases from Chennai, ~150 from Kolkata, ~200 each from Bangalore & Ahmedabad• Expect to reach ~2000 unique breast cancer patient FFPE samples and treatment outcomes data by 2016
Sapien Biosciences
WIP: Extensive Data Available for 858 Unique Patients
Br Ca Stages
Data set
0 1 2A 2B 3A 3B 3C 4
16 103 302 177 121 74 48 17
Demographics √ √ √ √ √ √ √ √
ER status 16 94 273 150 102 61 41 -
PR status 14 94 273 150 102 61 41 17
Her 2 status 11 71 189 95 70 36 14 17
Ki 67 2 23 37 24 17 8 - 5
CT/RT/HT 13/13/10
77/73/77 240/187/196
145/123/129
102/90/78 54/54/51 42/40/37 14/19/21
Recurrence* L=4; D=11 L=1; D=9 L=4; D=10 L=2; D=7 L=5; D=9 D=3
5 YR Fol-up 1 47 164 82 50 6 5 2
* Samples from original and recurrence surgery often available
Growing Inventory of Triple Negative Breast Cancers : High Unmet Need Area
1
6
6
2
21
Triple Negative Breast Cancer (from Hyderabad) Total = 18
1
2A
2B
3A
3B
3C
4
9
10
6
Triple Negative Breast Cancer (from Delhi) Total = 29
1
2A
2B
3A
Expect ~120 more TNBCs from these and other sites – very useful to analyse drug targets, prognostic markers, effective drugs
Sapien Biosciences
Colon Ca: Predicting Response to Topoisomerase Inhibitors
• Human DNA Topoisomerase I (topo I) inhibitors camptothecin and its analogues (CPTs), represent one of the most potent class of anti-cancer drugs• 3rd generation drugs in clinical trials
• Used extensively to treat colorectal, ovarian, pancreatic and small cell lung cancer, however 60-87% patients do not respond to these drugs.
• Hence, in partnership with a Boston company, Sapien is validating a biomarker in Indian colon cancer patients to stratify responders vs. non-responders.• Also performing cross-platform validation to Ventana in India
Sapien will commercialize the biomarker in India upon successful completion
2012 May 2015 Sapien Biosciences
21Saarum Sciences
R&D - Culturing Human Cancers for Annotated Panels
Objectives :
• Screen new chemical or biological entities for companies in actual disease samples
• Generate Indian cancer patient response data by combining in vitro assays with outcomes
• Systematically screen Indian cancers against ‘pill box’ to repurpose drugs
• Conduct gene profiling of Indian cancers
• Derive Indian cell lines a la ATCC
ADVANTAGE: Genetic diversity / disease state based variations mimic clinical heterogeneity
* Ongoing acquisition and culturing for more sample types
12 May 2015
Cancer Type Successfully cultured*
Hematological 5
Brain 11
Breast >40
Cervical 2
Colon 3
Endometrium 1
Lung 1
Oesophagus 1
Prostate 5
Renal 2Poster No : 2201820
• Cells being characterized for rate of proliferation, generation of stem cells, expressionof molecular & histological markers, response to drugs etc
Culturing Fresh Breast Cancer Tissues
12 May 2015 30
P0 Day 15 P1 Day 5 P2 Day 4
SB-Br-408
P1 Day 7 P2 Day 7 P3 Day 7
SB-Br-6045
Creating a Model of Epithelial Mesenchymal Transition
• Natural phenomenon occurring during early development. In cancer, EMT is involved in: • the initial steps of metastasis• Potentially involved in the formation of cancer stem cells
• Therapeutics targeting EMT will target the crucial step of metastasis and the formation of secondary sites of cancer.
• We have engineered a regulated model of human EMT* using normal human breast tissue that is being characterized for phenotypic assays
• The EMT model generated will be useful for• target discovery or validation, • ID & screening of new drugs/combinations • ID novel EMT/Metastasis biomarkers
* Applied for provisional Patent Poster No : 2201820Saarum Sciences
12 May 2015 24
myPLATELETTM – Enabling Tailored Anti-Platelet Therapy
• Theranostic product for Precision Medicine
• Proprietary combination of genetic and cell-based test to enable physicians to optimize drug and dose adjustments to personalize ANTI PLATELET THERAPY.
• Test validated & currently in use at Apollo and other hospitals
Sapien Biosciences
Scope & Scale of Sapien’s Biobank – 5 years from now
12 May 2015 25Sapien Biosciences
• ~0.5M patient samples and records capturing diversity of many Indian diseases, from Apollo and non-Apollo hospitals across the country
• Focused collections of disease-specific sample databases
• Annotated panels of individual tumour types, 500-5000 specimens each e.g., breast, H&N cancer
• Industry leader in India & contributing Member of international biobanking consortia, publications and conferences
• Strategic partnerships with proven leaders in genomics, proteomics, metabolomics
• High-end Mol & Cell Bio, Pathology, Biobank, IT, Bioinformatics cores to:
• Develop prognostics, diagnostics, theranostics to improve patient outcome and promote wellness
• Develop companion biomarkers, identify drug targets and help repurpose available drugs
• Launch 5-10 new diagnostic tests developed in-house and ~20 customized from partners
• NABL, CAP, Biobank accreditation
Acknowledgments
• Apollo management, and leadership across individual Apollo hospitals
• Diagnostic labs especially Pathology & Hematology
• Database, IT, Med Records departments
• AHERF – Incubation space and equipment for Sapien, Scientific advisors
• IICT – Indian Institiute of Chemical Technology – incubation space for Saarum
• Nishith Desai Associates – Law firm investing their expertise, experience and faith in us
• RSN Co – Chartered accountancy firm, investing their expertise, experience and faith in us
• EC members of Hospital committees, IRB members
12 May 2015 26Sapien-Saarum
R&D Infrastructure available to Sapien-Saarum
12-May-15 Introduction to Sapien Biosciences 28
Flow cytometry
Cell sorting
Fluorescent microscopy
Laser scanning confocal
SNPs, SNP arrays
Sequencing
Bioinformatics including pathway/ systems biology
Biacore
HPLC
GCMS
LC-MALDI-TOF
X-Ray diffraction
CD
Karyotyping
FISH
ISH
ELISAs
In-house @ Sapien / Apollo or at strategic collaborators
Propose Establishing Core Facilities for Advanced Tech Areas: High Density Tissue Microarray
12 May 2015 29
Many Advantages of TMA:
Array of tissues in small cores, at high density, to conserve tissue samples and reagents
• Imprinted on 3 inch glass slide
• Highly efficient - minimal usage of sample
• High throughput – process 100s of samples at a time
• Preserves tissue architecture – clinically relevant
• Semi-quantitative
• High demand worldwide
• Flexible formats
• Can be Stage-wise: 1-4
• Can be different tumours
• Can be tumour vs. normal tissue
Sapien Biosciences
Human Samples and Data have Enabled the Development of Many Drugs & Paired Diagnostics
http://www.cuttingedgeinfo.com/2013/oncology-spotlight-companion-diagnostics-drive-patient-recruitment/